Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
Open Access
- 17 June 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 34 (8), 2276-2278
- https://doi.org/10.1038/s41375-020-0907-9
Abstract
No abstract availableFunding Information
- José Carreras Leukämie-Stiftung (AH06-01)
This publication has 10 references indexed in Scilit:
- Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital AdmissionClinical Infectious Diseases, 2020
- The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammationLeukemia, 2020
- Clinical and demographic characteristics of patients dying from COVID‐19 in Italy vs ChinaJournal of Medical Virology, 2020
- COVID-19: combining antiviral and anti-inflammatory treatmentsThe Lancet Infectious Diseases, 2020
- Clinical and immunological features of severe and moderate coronavirus disease 2019JCI Insight, 2020
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Questioning the Effectiveness of Baricitinib for Pulmonary Manifestations of Rheumatoid ArthritisAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyLeukemia, 2015